Literature DB >> 29949466

Nanostructured lipid carriers-based thermosensitive eye drops for enhanced, sustained delivery of dexamethasone.

Zhenjie Mo1,2,3, Junfeng Ban1,2,3, Yan Zhang1,2,3, Youyun Du1,2,3, Yifeng Wen1,2,3, Xin Huang1,2,3, Qingchun Xie1,2,3, Lou Shen1,2,3, Shu Zhang1,2,3, Hong Deng1,2,3, Dongzhi Hou1,2,3, Yanzhong Chen1,2,3, Zhufen Lu1,2,3.   

Abstract

AIM: Nanostructured lipid carriers in-gel (NLCs-gel) were prepared to enhance and improve the ocular delivery of dexamethasone. Materials & methods: NLCs containing dexamethasone prepared by high-pressure homogenization were characterized and dispersed into thermosensitive gels (Pluronic F127 and F68 as gels material). In vitro drug release studies, ocular irritation tests, ex vivo corneal penetration and drug dynamics of NLCs and NLCs-gel were evaluated in aqueous humor.
RESULTS: NLCs-gel exhibited a rapid sol-gel transition at 34.4°C and presented nano-sized, narrowly distributed particles. Corneal penetration studies revealed steady sustained drug release (Ritger-Peppas); NLCs-gel increased ocular bioavailability by prolonging precorneal retention time and improving corneal permeation.
CONCLUSION: These findings suggest developing NLCs-gel for potential treatment of posterior segment eye diseases.

Entities:  

Keywords:  dexamethasone; nanostructured lipid carrier; ocular bioavailability; posterior segment eye disease; thermosensitive gel

Mesh:

Substances:

Year:  2018        PMID: 29949466     DOI: 10.2217/nnm-2017-0318

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  8 in total

1.  A simple coating method of PDMS microchip with PTFE for synthesis of dexamethasone-encapsulated PLGA nanoparticles.

Authors:  Zahra Mahmoodi; Javad Mohammadnejad; Sajad Razavi Bazaz; Ali Abouei Mehrizi; Mohammad Adel Ghiass; Massoud Saidijam; Rassoul Dinarvand; Majid Ebrahimi Warkiani; Masoud Soleimani
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

2.  Impact of Different Mucoadhesive Polymeric Nanoparticles Loaded in Thermosensitive Hydrogels on Transcorneal Administration of 5-Fluorouracil.

Authors:  Angela Fabiano; Anna Maria Piras; Lorenzo Guazzelli; Barbara Storti; Ranieri Bizzarri; Ylenia Zambito
Journal:  Pharmaceutics       Date:  2019-11-21       Impact factor: 6.321

3.  Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use.

Authors:  Eszter L Kiss; Szilvia Berkó; Attila Gácsi; Anita Kovács; Gábor Katona; Judit Soós; Erzsébet Csányi; Ilona Gróf; András Harazin; Mária A Deli; Mária Budai-Szűcs
Journal:  Pharmaceutics       Date:  2019-12-14       Impact factor: 6.321

Review 4.  Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.

Authors:  Mehrdad Afarid; Shirin Mahmoodi; Roghayyeh Baghban
Journal:  J Nanobiotechnology       Date:  2022-08-02       Impact factor: 9.429

5.  Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease.

Authors:  Sangeeta Kumari; Madhuri Dandamudi; Sweta Rani; Elke Behaeghel; Gautam Behl; David Kent; Niall J O'Reilly; Orla O'Donovan; Peter McLoughlin; Laurence Fitzhenry
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

6.  Preparation and study of two kinds of ophthalmic nano-preparations of everolimus.

Authors:  Zhan Tang; Lina Yin; Yawen Zhang; Wenying Yu; Qiao Wang; Zhajun Zhan
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

Review 7.  Dexamethasone Conjugates: Synthetic Approaches and Medical Prospects.

Authors:  Natallia V Dubashynskaya; Anton N Bokatyi; Yury A Skorik
Journal:  Biomedicines       Date:  2021-03-27

Review 8.  Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy-An Overview on Recent Advances.

Authors:  Shery Jacob; Anroop B Nair; Jigar Shah; Sumeet Gupta; Sai H S Boddu; Nagaraja Sreeharsha; Alex Joseph; Pottathil Shinu; Mohamed A Morsy
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.